The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationDifferent doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationImproving platelet transfusion safety: biomedical and technical considerationsAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice.Does bleeding affect patient-reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review.Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot studyState of the art in platelet function testing.Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.Pathogen-reduced platelets for the prevention of bleeding.Platelet function testing in pediatric patients.Transfusion efficacy of apheresis platelet concentrates irradiated at the day of transfusion is significantly superior compared to platelets irradiated in advance.Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies.A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy.Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
P2860
Q24186359-79E86180-249E-42E6-ABCD-77AEE3F9FF07Q24186913-8C18FF77-BF62-4680-AAA4-D80D7D28B58AQ24187751-4E92F449-C1B2-495B-A534-A963B1BC674FQ24198288-E07557C6-7A15-4460-BC11-30055431EE55Q24198774-287ECD79-3C89-49DE-9A71-B72EF1A02113Q24198795-1115B68E-F3C0-4E5A-97A5-DD4C9BB09C31Q24198832-CD14D73E-20FA-4AF9-A5C6-68F5446516ECQ26775408-A013866D-F5B9-4C3B-B407-2972AE9C77FEQ30248355-EFEB3E79-3763-4EC9-9724-82F3DACEEEECQ33409352-985D0A95-F039-4DE9-B84F-F12C7FCF12BCQ33410860-F5C95BEC-EAC6-49C1-9314-E731EBCF4B61Q33421355-B62AC190-115F-4776-9C07-EA559AB96108Q33429565-832CA2F9-0B4B-4A3B-B29C-1CF91D4E2B85Q33436425-2A2241B5-F7F7-48EF-BAA1-B028B00DEF50Q36802971-8F20A6BA-27EE-4B84-A7C2-835781AA8C91Q37265484-EABEF53F-086D-4C48-AD2A-AB6B79FDDAFBQ38653240-FFA39096-DBE3-4B09-BF81-75EE73F0F62FQ39202811-BF095083-AE66-4144-831F-69A6BD7E4772Q42725388-8F194728-6692-4AB7-A2F1-FD7C119D05D9Q47118226-EC826C8B-56F7-4B4B-BF66-681A9BF2E92CQ48273685-01ABBF61-54F1-42E1-8202-A9DC0EF32663Q51742200-BD414A59-ED6A-4C12-8BD9-7DE181F5836DQ57689300-3FF92486-2DF6-40DF-B662-40D9F5421F12
P2860
The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The challenges of measuring bl ...... ials of platelet transfusions.
@en
type
label
The challenges of measuring bl ...... ials of platelet transfusions.
@en
prefLabel
The challenges of measuring bl ...... ials of platelet transfusions.
@en
P2093
P2860
P356
P1433
P1476
The challenges of measuring bl ...... ials of platelet transfusions.
@en
P2093
Biomedical Excellence for Safer Transfusion Collaborative
Jeffrey McCullough
Michael F Murphy
Nancy Heddle
Richard Kaufman
Sherrill Slichter
Simon J Stanworth
P2860
P304
P356
10.1111/TRF.12058
P577
2013-01-10T00:00:00Z